Bridgeway Capital Management’s Altimmune ALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-50,600
| Closed | -$183K | – | 1231 |
|
|
2025
Q4 | $183K | Hold |
50,600
| – | – | ﹤0.01% | 1034 |
|
|
2025
Q3 | $191K | Buy |
+50,600
| New | +$195K | ﹤0.01% | 1024 |
|
|
2024
Q2 | – | Sell |
-34,100
| Closed | -$347K | – | 1271 |
|
|
2024
Q1 | $347K | Sell |
34,100
-27,600
| -45% | -$281K | 0.01% | 1005 |
|
|
2023
Q4 | $694K | Sell |
61,700
-70,000
| -53% | -$292K | 0.01% | 856 |
|
|
2023
Q3 | $342K | Hold |
131,700
| – | – | 0.01% | 982 |
|
|
2023
Q2 | $465K | Buy |
+131,700
| New | +$591K | 0.01% | 922 |
|
|
2021
Q1 | – | Sell |
-27,800
| Closed | -$314K | – | 1355 |
|
|
2020
Q4 | $314K | Sell |
27,800
-5,000
| -15% | -$58.9K | 0.01% | 1107 |
|
|
2020
Q3 | $433K | Sell |
32,800
-5,800
| -15% | -$116K | 0.01% | 951 |
|
|
2020
Q2 | $413K | Buy |
38,600
+2,500
| +7% | +$13.7K | 0.01% | 922 |
|
|
2020
Q1 | $116K | Hold |
36,100
| – | – | ﹤0.01% | 1161 |
|
|
2019
Q4 | $68K | Buy |
+36,100
| New | +$66.7K | ﹤0.01% | 1267 |
|
|
2018
Q2 | – | Sell |
-1,421
| Closed | -$49K | – | 1411 |
|
|
2018
Q1 | $49K | Sell |
1,421
-1,223
| -46% | -$61.3K | ﹤0.01% | 1360 |
|
|
2017
Q4 | $158K | Hold |
2,644
| – | – | ﹤0.01% | 1298 |
|
|
2017
Q3 | $184K | Hold |
2,644
| – | – | ﹤0.01% | 1291 |
|
|
2017
Q2 | $254K | Buy |
2,644
+663
| +33% | +$110K | ﹤0.01% | 1239 |
|
|
2017
Q1 | $482K | Sell |
1,981
-642
| -24% | -$343K | 0.01% | 1086 |
|
|
2016
Q4 | $2.56M | Hold |
2,623
| – | – | 0.03% | 483 |
|
|
2016
Q3 | $2.28M | Hold |
2,623
| – | – | 0.03% | 488 |
|
|
2016
Q2 | $1.92M | Buy |
2,623
+642
| +32% | +$439K | 0.03% | 538 |
|
|
2016
Q1 | $1.12M | Buy |
1,981
+833
| +73% | +$426K | 0.02% | 716 |
|
|
2015
Q4 | $654K | Buy |
1,148
+167
| +17% | +$83.3K | 0.01% | 949 |
|
|
2015
Q3 | $392K | Buy |
981
+109
| +13% | +$51.6K | 0.01% | 1141 |
|
|
2015
Q2 | $471K | Buy |
872
+34
| +4% | +$17.2K | 0.01% | 1101 |
|
|
2015
Q1 | $410K | Hold |
838
| – | – | 0.01% | 1170 |
|
|
2014
Q4 | $455K | Hold |
838
| – | – | 0.01% | 1109 |
|
|
2014
Q3 | $448K | Sell |
838
-29
| -3% | -$15.2K | 0.01% | 1129 |
|
|
2014
Q2 | $367K | Hold |
867
| – | – | 0.01% | 1208 |
|
|
2014
Q1 | $476K | Buy |
867
+29
| +3% | +$16.9K | 0.01% | 1097 |
|
|
2013
Q4 | $468K | Hold |
838
| – | – | 0.01% | 1067 |
|
|
2013
Q3 | $528K | Buy |
838
+227
| +37% | +$130K | 0.02% | 1012 |
|
|
2013
Q2 | $291K | Buy |
+611
| New | +$303K | 0.01% | 1183 |
|
Other funds holding ALT
VCM
VPM
N
Bridgeway Capital Management's ALT Position: Q1 2026 in Review
Bridgeway Capital Management sold out of Altimmune (ALT) in Q1 2026, closing a stake of 50,600 shares — an estimated $183K sold.
Bridgeway Capital Management first reported a position in ALT in Q2 2013 and held it in 31 quarters. The position peaked at $2.56M in Q4 2016. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.
- Bridgeway Capital Management reported no remaining Altimmune position as of Q1 2026 after selling out during the quarter.
- Bridgeway Capital Management sold 50,600 Altimmune shares in Q1 2026, an estimated $183K.
- Bridgeway Capital Management first reported a position in Altimmune in Q2 2013 and held it in 31 quarters.
- Bridgeway Capital Management's Altimmune position peaked at $2.56M in Q4 2016.
- 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.
Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.